Peijia Medical's Journey to EU Medical Device Approval
Peijia Medical Limited, renowned for its advancements in medical technology, has made a significant leap forward by submitting its registration application for the EU Medical Device Regulation (EU MDR) CE Mark for the GeminiOne Transcatheter Edge-to-Edge Repair (TEER) System. This innovative medical device is designed specifically for the treatment of mitral regurgitation and is a product of Peijia Medical's dedication to enhancing patient care.
Strategic Global Expansion
The submission of the CE Mark application represents a landmark achievement in Peijia Medical's strategic plan to expand its international footprint. Collaborating with HighLife SAS, the European partner, the company aims to establish a strong presence in major markets, addressing the growing need for advanced medical solutions.
Innovative Features of the GeminiOne System
The GeminiOne TEER System is not just another medical device; it incorporates state-of-the-art engineering that makes it stand out. A unique sliding groove mechanism allows for a longer coaptation length while ensuring the system remains compact. This design is crucial for ensuring ease of use during procedures, especially in patients with diverse anatomical structures.
Additionally, the system features an independent leaflet grasping design that significantly simplifies the procedure. This is complemented by an auto-locking mechanism, which prevents the challenges of repeated locking and unlocking during medical interventions, thereby enhancing operational efficiency.
Furthermore, GeminiOne boasts a multi-angular detachment capability, allowing healthcare providers to cater to different anatomical variations, thus providing a personalized treatment approach for each patient.
Regulatory Progress and Approvals
The road to regulatory approval for GeminiOne has been marked by significant milestones. In addition to the EU submission, the application for registration has been endorsed by the National Medical Products Administration (NMPA) of China, where it is currently under active review. Furthermore, in a significant move for further development, the U.S. Food and Drug Administration (U.S. FDA) has granted Investigational Device Exemption (IDE) approval, allowing for an Early Feasibility Study (EFS) in the United States.
This multi-faceted approach demonstrates Peijia Medical's commitment to ensuring that their innovative treatment options are available to patients as quickly and safely as possible.
Commitment to Patient Care
Peijia Medical remains dedicated to advancing medical technologies that promote the well-being of patients suffering from mitral regurgitation. Their ongoing efforts in regulatory registrations across Europe and China aim to deliver safe and effective solutions that can transform patient outcomes.
About Peijia Medical
Founded in 2012 and headquartered in Suzhou, China, Peijia Medical focuses on the fast-growing market for interventional medical devices. Their vision is to evolve into a world-class platform that delivers comprehensive treatment solutions for structural heart and neurovascular diseases. With a portfolio that includes several TAVR systems and nearly twenty neurointerventional devices, Peijia is on the frontier of medical innovation. They host a range of product candidates at varying stages of development, ensuring that they are equipped to meet the challenges of tomorrow's healthcare landscape.
Frequently Asked Questions
What is the GeminiOne TEER System?
The GeminiOne TEER System is an innovative medical device developed by Peijia Medical for the treatment of mitral regurgitation, featuring advanced design elements for enhanced procedural efficiency.
What does the CE Mark application signify?
The CE Mark application indicates that a medical device meets European health and safety regulations, allowing it to be marketed in Europe.
How does Peijia Medical support its global expansion?
Peijia Medical collaborates with partners like HighLife SAS to facilitate the regulatory processes and enhance its international reach in key markets.
What approvals has GeminiOne received so far?
The GeminiOne system has received applications from both the EU and China, and it has also been granted U.S. FDA Investigational Device Exemption for clinical studies.
What is Peijia Medical's mission?
Peijia Medical aims to provide innovative solutions and advance patient care in the field of interventional procedures, focusing on structural heart and neurovascular diseases.
